Current Research Studies

Cancer – NCT03971799: Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia

Condition or Therapy:

Relapsed/refractory acute myeloid leukemia in children and young adults

 

 

Category:

Cancer and Blood Disorders
Study Number: NCT03971799

What is the goal of this study?

These are the main purposes of this study:

  1. Test if it is feasible to grow the chimeric antigen receptor-expressing T cells (CD33CART) in the laboratory.
  2. Test the safety of giving the CD33CART cells to children and young adults with acute myeloid leukemia. We will watch for side effects.
  3. Test how your disease responds when you are given the CD33CART cells after a chemotherapy regimen.
  4. Measure how long the CD33CART cells live in your blood and/or bone marrow. We will look for the effects on your immune cells.

This trial is in partnerships with Fred Hutch and Seattle Cancer Care Alliance.

Who can join the study?

This study might be a good fit for children and young adults who:

  • Are ages 1 to 34 years old.
  • Have relapsed/refractory acute myeloid leukemia without a central nervous system disease.
  • Have a suitable allogeneic HCT donor and a performance status of more than 50%.

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

Please email or call us at 206-987-2106 to learn more about the study.


Study Location(s):

Seattle Children's Hospital campus 

Principal Investigator:

Dr. Katherine Tarlock
and Dr. Corinne Summers

Center for Clinical and Translational Research